Hypersensitivity, severe liver and kidney function disorders, blood diseases, glucose-6-phosphate dehydrogenase deficiency, severe cardiac diseases, pregnancy, breast-feeding, age up to 6 weeks of life (Table).
Enhances the effect of indirect anticoagulants, sulfonylurea derivatives, increases the toxicity of methotrexate. NSAIDs increase the effect of brifecase with the development of side effects. Simultaneous treatment with diuretics and Brifecase increases the risk of thrombocytopenia, especially in elderly patients. When administered concomitantly with chloridine, the antimicrobial effect is enhanced.
From the cardiovascular system and blood (hematopoiesis, hemostasis): leukopenia, neutropenia, thrombopenia, agranulocytosis, megaloblastic anemia.
From the gastrointestinal tract: nausea, vomiting, diarrhea, pseudomembranous colitis (extremely rare).
From the genitourinary system: crystalluria, hematuria, interstitial nephritis.
Allergic reactions: Quincke's edema, Stevens-Johnson syndrome, Lyell's syndrome, skin rash.
Other: purpura, a violation of the function of the thyroid gland.
Respiratory tract infections (including tonsillitis, pharyngitis, acute and chronic bronchitis, bronchiectatic disease, lung abscess, pneumonia), infections of the genitourinary system (including gonococcal urethritis, cystitis, pyelonephritis, prostatitis), gastrointestinal infections (including enteritis, typhoid fever, paratyphoid, dysentery, cholecystitis, cholangitis), skin and soft tissue infections (including including pyoderma, furunculosis, wound infection), septicemia, brucellosis.
In a dry place, protected from light, at a temperature not exceeding 25 °C.
Keep out of reach of children.
The shelf life of the drug Bethesada®tablets 0.12 g — 5 years.
tablets 0.48 g — 2 years.
concentrate for the preparation of solution for infusions 0.48 g/5 ml — 5 years.
Do not use after the expiration date indicated on the package.
1 tablet contains sulfamethoxazole 0.1 g and trimethoprim 0.02 g (Table 0.12 g) or sulfamethoxazole 0.4 g and trimethoprim 0.08 g (Table 0.48 g), in a package of 10 and 20 pcs.
1 ml of solution for infusions-sulfamethoxazole 0.08 g and trimethoprim 0.16 g, in ampoules of 5 ml, in a contour cell package of 5 ampoules, in a cardboard pack of 2 packages.
Contraindicated. Breastfeeding should be discontinued for the duration of treatment.
Inside, during or after a meal (the dose is selected individually), for uncomplicated infections: adults and children over 12 years of age — 1-2 tables. 2 times a day, children from 6 to 12 years — 1 table. 2 times a day, in severe bacterial infection: 2-3 tables each. 2 times a day. The course duration is 5-14 days. In severe and / or chronic forms of infectious diseases, it is permissible to increase the single dose by 30-50%. In the case of prolongation of the course of treatment for more than 5 days and/or an increase in the dose, it is necessary to conduct hematological control, if the blood picture changes, the use of folic acid at 5-10 mg/day is necessary.
IV drip slowly (for 60-90 minutes). Pre-diluted in 5% glucose solution, 0.9% sodium chloride solution or Ringer's solution. The calculation of body weight is made by trimethoprim. Adults: in severe infections-8-10 mg / kg/day in 2-3 injections, in pneumocystic pneumonia-20 mg/kg/day in 3-4 injections. The course of treatment is 3 weeks. Children older than 2 months: in severe infections and pneumocystis pneumonia — 15-20 mg/kg / day in 3-4 injections.
J01EE01 Co-trimoxazole [sulfamethoxazole trimethoprim]
